Introduction
Vertebral compression fractures (VCF) are one of the most frequent osteoporosis-related diseases, especially in post-menopausal women [1] , while, for younger patients, vertebral fractures can be caused either by trauma or cancer. VCF are currently treated through mini-invasive surgical procedures: vertebroplasty (VP), by which a cement is injected into the fractured vertebral body, and kyphoplasty (KP), during which a cavity in the fractured vertebra is created before filling it by injecting the cement, in order to help the restoration of the original vertebral height. Both procedures require an easily injectable material that has also to be highly radiopaque, since both are carried out under fluoroscopic control.
Most of the cements currently used in surgery are based on a polymeric matrix (mainly polymethyl-metacrylate, PMMA), but they have many drawbacks such as mechanical mismatch of the compressive strength, excessive temperature raising during their setting and, being not resorbable, they cannot be replaced by new healthy tissue [2] . Calcium sulfate-based injectable cements, like Cerament by Bone Support, can be a good alternative since they are biocompatible, bioresorbable and show mechanical properties similar to those of cancellous bone [3, 4] . In order to achieve all the requirements of an injectable bone cement for vertebroplasty, composite materials can be developed. In the present work, basing on the main author's patent application PCT/IB2011/052094 [5] , we combined type III α-calcium sulfate hemihydrate with mesoporous particles of a bioactive glass and a radiopaque glass-ceramic phase. Moreover, the mesoporous bioactive glass (MBG) was obtained through the spray-drying technique, which allows for a faster and more repeatable process [6] .
MBG, in fact, are known to be highly bioactive and to be able to release silicon and calcium, which had been proven to be osteoinductive elements [7] , but they are usually obtained through a time-consuming sol-gel synthesis, combined with an evaporation-induced self-assembly (EISA) process [8] . Basing on the work of Andersson et al. [9] , spherical mesoporous particles of bioactive glass were produced by spray-drying and they were used as dispersed phase in the calcium sulfate matrix to impart a very high bioactivity to the material.
A further dispersed phase was added, consisting of a glass-ceramic bioactive phase containing zirconia (ZrO 2 ) to enhance the radiopacity of the injected paste.
Here, the characterization of the composite cement is carried out and results are discussed.
Experimental
70%wt of type III dental α-calcium sulfate hemihydrate (CSH) was mixed with 10%wt of spraydried mesoporous bioactive particles (SD-MBP) and 20%wt of glass-ceramic radiopaque particles (SCNZ gc ), in order to obtain the composite powder phase of the injectable cement.
The mesoporous bioactive particles were produced by combining the sol-gel method [8, 10] with the aerosol-assisted spray-drying technique [9] . The sol was prepared by dissolving 2.2 g of Pluronic P123 (EO 20 PO 70 EO 20 , where "EO" is poly(ethylene glycol) and "PO" is poly(propylene glycol)) in 8.0 g of ethanol; then, in a separate batch, 10.4 g of TEOS (tetraethyl orthosilicate) were pre-hydrolyzed for 20 minutes with 5.4 g of diluted hydrochloric acid (pH 2) and 12.0 g of ethanol.
The two solutions were mixed together and stirred for 20 minutes, while 2.95 g of CaNT (calcium nitrate tetrahydrate) were pre-dissolved in 3.4 g of ethanol. Finally, the CaNT solution was poured into the previous one and the final solution was mixed for at least 20 minutes before spraying, using the Mini Spray-Dryer B-290, equipped with the Inert-Loop B-295 (both from Büchi), needed when using flammable solvents. The collected powder was calcined at 973 K for 5 hours.
The glass-ceramic phase SCNZ gc , composition SiO 2 /CaO/Na 2 O/ZrO 2 57/30/6/7% mol, was obtained by melting and casting a mixture of silica (SiO 2 ), calcium carbonate (CaCO 3 ), sodium carbonate (Na 2 CO 3 ) and zirconia (ZrO 2 ) at 1873 K; the obtained frit was milled and ceramized at 1423 K for 3 hours, then the obtained glass-ceramic was milled again and sieved under 20 µm.
All the reagents used for the mesoporous glass and the glass-ceramic were purchased from Sigma-Aldrich and used as received.
The injectable paste was obtained by mixing with a spatula the powder phase described above into a syringe with bidistilled water, using a liquid to powder (L/P) ratio ranging from 0.4 to 0.5 mL/g. The cement was then injected through a vertebroplasty needle into plastic molds having the required dimensions to get the final massive samples. Comparisons with the commercial control Cerament by Spine Support were carried out; Cerament ® samples were prepared by using the given mixing device and then injecting the paste through the vertebroplasty needle in the plastic molds.
Mechanical compressive strength was tested by using a Zwick/Z100 machine from Zwick/Roell. All samples were tested with a load cell of 5 kN and with a speed of lowering of the load maintained constant at 1 mm/min, both in wet and dry conditions, i.e. after 24 hours and 7 days from their preparation. The tested samples were cylindrical, with theoretical diameter of 13.5 mm and height of 10.0 mm. Compressive strength (σ c ) is intended to be the maximum load born by the sample (F max ) divided by the sample's cross area (A): σ c = F max /A.
(1) Resorbability was assessed by soaking massive samples (13.5 mm in diameter and 5 mm in height) in 25 mL of simulated body fluid (SBF) solution [11] , keeping them at 310 K in static incubator and refreshing their medium every 48 hours, to simulate the recirculation of fluids in the human body, until the final sample was completely resorbed. The resorption rate was monitored by measuring and weighing the extracted dried samples.
Bioactivity was proven by soaking samples (13.5 mm in diameter and 5.0 mm in height) in 100 mL of SBF for 7 days without refreshing the solution. Samples were kept in an orbital shaker at 310 K and 120 rpm. After extraction, the massive samples and the dissolution powder were collected, dried and tested by FE-SEM (MERLIN ZEISS equipped with EDS analyzer).
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Cytocompatibility was tested through MTT assay by culturing rat bone marrow stromal cells (BMSCs) in non-contact multi-well plates using cylindrical samples with 5 mm in diameter and 2 mm in height, sterilized by γ-rays with a dose of 25 kGy. Alkaline phosphatase (ALP) activity was tested using samples with the same shape and dimensions.
Ex-vivo injectability has been proven by injecting the cement paste through sheep explanted vertebrae.
Results and Discussion
The optimized liquid to powder ratio allowed to obtain a paste that could be extruded through a 15 gauge syringe, as can be seen in Fig. 1 . Figure 1 . A) Picture of a syringe after the injection of Spine-Ghost, coupled with a 15 gauge vertebroplasty needle; B) Spine-Ghost extruded on a paper sheet to prove its injectability.
Through compressive strength tests, a comparison between Spine-Ghost, its type III dental α-calcium sulfate matrix and the chosen commercial control Cerament, from Spine Support, was carried out. The proposed composite cement, after setting and in both wet and dry conditions, showed significantly higher mechanical properties if compared with the equivalent samples of the commercial product, while similar properties were found for the composite and its matrix, so that it can be concluded that the two chosen dispersed phases do not affect the final behavior of the material. Moreover, the compressive strength found for Spine-Ghost, being about 15 MPa, is comparable to the one of the healthy vertebral cancellous bone [12] , thus the developed material allows for a good mechanical match with the host living tissue.
Spine-Ghost resorption samples completely dissolved in SBF after 35 days of soaking, while the commercial control Cerament was totally dissolved after 28 days of immersion. The two results are comparable, although Spine-Ghost performed 25% better than the control, demonstrating that it has a sufficiently slow resorption behavior, due to a superficial erosion mechanism which is characteristic of calcium sulfate when immersed in a water solution. Fig. 2 shows the characteristic leaf-like features of precipitated hydroxyapatite (HAp), which was found in the dissolution powder collected after 7 days of SBF soaking of a Spine-Ghost massive sample. Fig. 2B displays its relative EDS spectrum, which enlightens the significant presence of phosphorus, that is not contained in the starting cement composition and it thus derives from the precipitated phase.
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Both the morphological observations and the compositional data confirmed the high bioactivity of Spine-Ghost. Preliminary cell tests carried out on Spine-Ghost massive samples were devoted to the evaluation of the viability of rat BMSCs through an MTT test and their ALP activity. In these preliminary tests, Spine-Ghost showed an equivalent or even better behavior than its commercial control, proving to be cytocompatible and supportive of the ALP activity, which means the material is able to stimulate osteoblasts for the formation of new bone tissue. Ex-vivo tests carried out on explanted sheep vertebrae proved the feasibility of the injection of the proposed composite cement in the chosen animal model; the material resulted to be radiopaque enough for the fluoroscopic procedure and less viscous than Cerament, so easier to be injected. The injected Spine-Ghost paste set in situ in about 30 minutes and allowed for the restoration of the original mechanical properties of the vertebrae, which, after the treatment, could bear higher loads than the physiological ones.
Conclusions
An injectable composite cement, highly bioresorbable and highly bioactive, was successfully obtained. Spine-Ghost is particularly envisaged for vertebroplasty application, since it proved to be radiopaque enough for the fluoroscopic surgical procedure, it showed, once set, a mechanical strength comparable to the compressive strength of the healthy vertebral trabecular bone and it could be easily injected into the ex-vivo sheep vertebra, selected as animal model. Extensive cell tests and in-vivo tests on rats and sheep are scheduled for the next future.
